Kunkel Lori Anne 4

What Happened

• Lori Anne Kunkel, a director of Enliven Therapeutics (ELVN), was granted a derivative award for 17,126 shares on February 12, 2026. The transaction is reported at $0.00 (derivative), indicating an award of equity (e.g., options or RSUs) rather than an open-market purchase or sale. No immediate exercise or sale was reported.

Key Details

• Transaction date: 2026-02-12; Form 4 filed: 2026-02-17 (filed 5 days after the transaction; appears later than the typical 2-business-day Form 4 deadline).
• Reported price: $0.00 (derivative award).
• Shares involved: 17,126 shares granted.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting or (ii) the date of the 2027 annual meeting, provided Kunkel continues as a non-employee director through the applicable vesting date.
• Transaction code: A (grant/award/acquisition).

Context

• This is a director compensation award (derivative grant) and not an open-market purchase or sale. The award will not convert to vested shares until the stated vesting condition is met; there was no immediate sale or cashless exercise reported. Director grants are common for non-employee board members and do not by themselves indicate insider buying or selling sentiment. For complete details (exercise price if any, total holdings after the grant), review the full Form 4 filing (Accession: 0001536368-26-000003).